FDA Approves Cathflo Activase

Article

SOUTH SAN FRANCISCO, Calif-The US Food and Drug Administration (FDA) has approved Cathflo Activase (Alteplase) for the restoration of function to central venous access devices (CDADs) that have become occluded by a blood clot, or thrombus.

Cathflo Activase is a thrombolytic agent that works by targeting substances that cause blood to clot. The device dissolves the clot and restores function to the CVAD. This is the first thrombolytic agent approved by the FDA for this purpose.

CVADs, a broad term that includes many types of catheters, are used to withdraw blood or administer medications and nutritional fluids to critically ill patients. There are an estimated 5 million catheters used in US hospitals annually, with 25% of these estimated to become blocked.

Cathflo Activase works by activating plasminogen that dissolves fibrin-a substance that causes blood to clot. This process breaks down the thrombus and leaves the CVAD functioning properly.

FDA approval of the device is based on two Phase III clinical trials that tested safety and efficacy in the restoration of CVAD function during the process.

The device has been created by Genetch, Inc., based in South San Francisco, California.

For more information about the company, log onto www.gene.com

Related Videos
Medical investigators going over data. (AdobeStock 589197902 by Wasan)
CDC logo is seen on a laptop. (Adobe Stock 428450603 by monticellllo)
Association for the Health Care Environment (Logo used with permission)
Ambassador Deborah Birx, , speaks with Infection Control Today about masks in schools and the newest variant.
mRNA technology  (Adobe Stock 485886181 by kaptn)
Ambassador Deborah Birx, MD
Woman lying in hospital bed (Adobe Stock, unknown)
Photo of a model operating room. (Photo courtesy of Indigo-Clean and Kenall Manufacturing)
GIANTmicrobes at the 2023 APIC Annual Conference and Exhibition.  (Photo by the author)
Related Content